Flash Glucose-Sensing Technology as a Replacement for Blood Glucose Monitoring for the Management of Insulin-Treated Type 2 Diabetes: a Multicenter, Open-Label Randomized Controlled Trial by Haak, T et al.
ORIGINAL RESEARCH
Flash Glucose-Sensing Technology as a Replacement
for Blood Glucose Monitoring for the Management
of Insulin-Treated Type 2 Diabetes: a Multicenter,
Open-Label Randomized Controlled Trial
Thomas Haak . He´le`ne Hanaire . Ramzi Ajjan . Norbert Hermanns .
Jean-Pierre Riveline . Gerry Rayman
Received: November 9, 2016 / Published online: December 20, 2016
 The Author(s) 2016. This article is published with open access at Springerlink.com
ABSTRACT
Introduction: Glycemic control in participants
with insulin-treated diabetes remains
challenging. We assessed safety and efficacy of
new flash glucose-sensing technology to replace
self-monitoring of blood glucose (SMBG).
Methods: This open-label randomized
controlled study (ClinicalTrials.gov,
NCT02082184) enrolled adults with type 2
diabetes on intensive insulin therapy from 26
European diabetes centers. Following 2 weeks of
blinded sensor wear, 2:1 (intervention/control)
randomization (centrally, using biased-coin
minimization dependant on study center and
insulin administration) was to control (SMBG)
or intervention (glucose-sensing technology).
Participants and investigators were not masked
to group allocation. Primary outcome was
difference in HbA1c at 6 months in the full
analysis set. Prespecified secondary outcomes
included time in hypoglycemia, effect of age,
and patient satisfaction.
Results: Participants (n = 224) were
randomized (149 intervention, 75 controls). At
6 months, there was no difference in the change
in HbA1c between intervention and controls:
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-3.1 ± 0.75 mmol/mol, [-0.29 ± 0.07%
(mean ± SE)] and -3.4 ± 1.04 mmol/mol
(-0.31 ± 0.09%) respectively; p = 0.8222. A
difference was detected in participants aged
\65 years [-5.7 ± 0.96 mmol/mol
(-0.53 ± 0.09%) and -2.2 ± 1.31 mmol/mol
(-0.20 ± 0.12%), respectively; p = 0.0301].
Time in hypoglycemia \3.9 mmol/L (70 mg/
dL) reduced by 0.47 ± 0.13 h/day [mean ± SE
(p = 0.0006)], and \3.1 mmol/L (55 mg/dL)
reduced by 0.22 ± 0.07 h/day (p = 0.0014) for
intervention participants compared with
controls; reductions of 43% and 53%,
respectively. SMBG frequency, similar at
baseline, decreased in intervention participants
from 3.8 ± 1.4 tests/day (mean ± SD) to
0.3 ± 0.7, remaining unchanged in controls.
Treatment satisfaction was higher in
intervention compared with controls (DTSQ
13.1 ± 0.50 (mean ± SE) and 9.0 ± 0.72,
respectively; p\0.0001). No serious adverse
events or severe hypoglycemic events were
reported related to sensor data use. Forty-two
serious events [16 (10.7%) intervention
participants, 12 (16.0%) controls] were not
device-related. Six intervention participants
reported nine adverse events for sensor-wear
reactions (two severe, six moderate, one
mild).
Conclusion: Flash glucose-sensing technology
use in type 2 diabetes with intensive insulin
therapy results in no difference in HbA1c
change and reduced hypoglycemia,
thus offering a safe, effective replacement for
SMBG.
Trial registration: ClinicalTrials.gov identifier:
NCT02082184.
Funding: Abbott Diabetes Care.
Keywords: Flash sensor glucose technology;
Glucose monitoring; Insulin; Type 2 diabetes
INTRODUCTION
The number of people with diabetes is increasing
globally with 90% having type 2 diabetes, a fifth
of whom are on insulin treatment. A significant
proportion of adults with insulin-treated type 2
diabetes are less than 65 years of age and
frequently have poor glycemic control [1, 2].
Improving glycemia reduces the risk of diabetes
complications and is a key management objective
[3]. However, intensification of insulin therapy
increases the risk of hypoglycemia [4] which is
associated with adverse clinical outcome [5],
impacts on quality of life [6], and increases
treatment costs secondary to hospital
admissions, ambulance call-outs, and clinic
attendance [7]. Glycated hemoglobin (HbA1c),
the gold standard for assessment of glycemic
control, is unable to reflect hypoglycemic risk or
indicate glucose variability, which recent reports
suggest are associated with inferior clinical
outcome [8, 9]. Detection of hypoglycemia or
glucose variability can be difficult with
self-monitoring of blood glucose which is
usually the main method used for
self-management and adjusting insulin therapy.
For participants on intensive insulin therapy, four
or more blood glucose tests are required daily to
safely and effectively adjust insulin doses. This is
not always achieved because of the pain and
inconvenience associated with this method of
glucose testing [10, 11]. A tool that can support a
more comprehensive assessment of glycemia is
continuous glucose monitoring; however,
current devices are costly, require repeated
calibration, and are constantly attached to the
patient, all key factors preventing widespread use.
There is a need for a new method of glucose
monitoring that is affordable and provides clear,
comprehensive glucose data with minimal
patient inconvenience.
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We used a novel sensor-based flash glucose
monitoring system (FreeStyle LibreTM; Abbott
Diabetes Care, Witney, UK). The small,
single-use, factory-calibrated, on-body sensor
utilizes wired enzyme technology (osmium
mediator and glucose oxidase enzyme
co-immobilized on an electrochemical sensor)
to continuously monitor interstitial glucose
levels. The sensor is worn on the back of the
arm for up to 14 days and automatically stores
glucose data every 15 min. A real-time glucose
level may be obtained as often as every minute
by scanning the sensor with the reader. A
glucose trend arrow (indicating rate and
direction of change in glucose levels) and a
graphical trace of glucose values for the
previous 8-h period are also displayed on the
screen. Data are transferred by radio frequency
identification (RFID) from the sensor to the
reader memory which stores historical sensor
data for 90 days. This data can be uploaded
using the device software to generate summary
glucose reports (including an ambulatory
glucose profile) for review by the patient at
home or in clinic with their healthcare
professional (HCP) [12].
The aim of our study was to assess the role of
this new category of glucose-sensing technology
on glycemic control in individuals with type 2
diabetes using intensive insulin therapy or
continuous subcutaneous insulin infusion
(CSII).
METHODS
Study Design and Participants
We conducted this 6-month, prospective,
open-label, non-masked, two-arm randomized
controlled study at 26 European diabetes
centers, eight in France, ten in Germany, and
eight in the UK (Supplementary Material p. 1).
We enrolled participants aged 18 years or
older with type 2 diabetes treated with insulin
for at least 6 months and on their current
regimen (prandial only or prandial and basal
intensive insulin therapy or CSII therapy) for
3 months or more, an HbA1c level
58–108 mmol/mol (7.5–12.0%), self-reported
regular blood glucose testing (more than
10/week for at least 2 months prior to study
entry), and were considered by the investigator
to be technically capable of using the flash
sensor-based glucose monitoring system. At
each study center, any potentially eligible
patient from the general diabetes population
was invited to participate in the study.
Participants were not included if they had
any other insulin regimen to that described
above; a total daily dose of insulin C1.75 units/
kg on study entry; had severe hypoglycemia
(requiring third-party assistance) [13], diabetic
ketoacidosis, or hyperosmolar-hyperglycemic
state in the preceding 6 months; known
allergy to medical-grade adhesives; used
continuous glucose monitoring within the
previous 4 months; were pregnant or planning
pregnancy; were receiving steroid therapy for
any condition; or were considered by the
investigator to be unsuitable to participate.
Approval was given by the appropriate
competent authorities in each country. All
procedures followed were in accordance with
the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1964, as revised in
2013. Informed consent was obtained from all
patients for participation in the study.
Randomization and Masking
Participants were centrally randomized in a 2:1
ratio to sensor-based flash glucose monitoring
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(intervention group) or to self-monitoring of
blood glucose (control group) by an interactive
web response system (IWRS) using biased-coin
minimization, with study center and insulin
administration as prognostic factors. The
intention of a 2:1 randomization ratio was to
ensure a sufficient number of participants in the
intervention arm to complete an additional
6-month, open-access study phase. Participants,
investigators, and study staff were not masked
to group allocation.
Procedures
Following consent, screening, and enrollment,
all participants wore a system locked into
masked mode for the 14-day baseline period
and were asked to scan their sensor every 8 h.
Sensor glucose measurements were blinded (not
visible) to participants and investigators during
this phase. Glucose management was supported
by continuation of their current regimen for
blood glucose monitoring using the strip-port
built into the reader and compatible test strips
(Abbott Diabetes Care, Witney, Oxon, UK).
Participants were asked to record blood
glucose levels in a glucose diary and to log
other events (e.g., severe hypoglycemia) in an
event diary. Participants with sensor data for at
least 50% of the blinded wear or at least 650
individual sensor readings (only two subjects
did not meet this criterion and withdrew) were
centrally randomized to intervention or control
group.
For the 6-month treatment phase
(post-randomization), the sensor-based glucose
monitoring system was unblinded for
intervention participants to continuously use
sensor glucose data for self-management,
including insulin dose decisions, in
accordance with the product labelling. No
training was provided to these participants for
interpretation of glucose sensor data. Their
historical data was uploaded at subsequent
study visits and glucose reports were generated
for review by the HCP with the participant,
using the device software [12].
Control participants self-managed their
glucose levels utilizing a standard blood
glucose device (Abbott Diabetes Care, Witney,
UK) and a glucose diary for the duration of the
study, wearing a blinded sensor again for the
last 2 weeks of the study.
Between randomization and day 194,
intervention and control participants had two
visits. At these visits, participants’ glucose
control was reviewed with an HCP and the
effects of diet/lifestyle on glucose trends and
insulin dose modifications were discussed.
There was no preset algorithm for insulin
adjustments mandated by the protocol in
order to reflect ‘‘real-world’’. However,
common principles were applied that included
avoidance of hypoglycemia, optimization of
fasting glucose levels, and reduction of
postprandial glucose excursions. Intervention
participants had a safety visit (day 45) as the
device was not on-market when the study
commenced.
HbA1c was measured in all participants at
baseline, 3 and 6 months with analysis by a
central laboratory (ICON Laboratories, Dublin,
Ireland).
All participants completed quality of life and
patient-reported outcome questionnaires
[14–16] prior to other study activities on day 1
and on day 194.
Outcomes
The primary outcome was the difference in
HbA1c between intervention and control
groups at 6 months. Prespecified secondary
endpoints were subgroup analyses by age (less
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than and 65 years or older), sensor-derived
glycemic measures from baseline to days
194–208, frequency of glucose finger-sticks and
sensor scans per day during the study period,
system utilization for days 15–208 (defined as
the percentage of data collected, assuming
continuous device wear), and change in total
daily dose of insulin, body mass index (BMI),
weight, and participant questionnaire
responses. Sensor-derived glycemic measures
comprised number and duration of
hypoglycemic events (\3.9 mmol/L
[70 mg/dL], and \3.1 mmol/L [55 mg/dL]);
time in range (3.9–10.0 mmol/L [70–180 mg/
dL]), number and duration of hyperglycemic
events ([10.0 mmol/L [180 mg/dL], and [13.3
mmol/L [240 mg/dL]), mean glucose, and
glucose variability measures [17–19]). An event
was defined as at least two consecutive readings,
at 15-min intervals, outside the predefined
glucose range (the end of an episode was one
reading at or inside the predefined range).
Secondary endpoints reported in the clinical
study report and not here, include change in
HbA1c from baseline to day 105, proportion of
participants with reduction in HbA1c of
C5.5 mmol/mol (0.5%) from baseline, or
achieving HbA1c B 58 mmol/mol (7.5%),
post-prandial hyperglycemia, blood pressure,
lipid levels, HCP questionnaire responses,
emergency room visits, hospital admissions,
additional clinic time, lancet use and
non-insulin medication use.
Results for the user questionnaire
(intervention participants only) were assessed
at 6 months. Patient-reported outcome and
quality of life (QoL) measures were assessed
using validated questionnaires: Diabetes
Distress Scale (DDS) [14], Diabetes Quality of
Life (DQoL) [15], and Diabetes Treatment
Satisfaction (DTSQs and DTSQc) [16].
Safety endpoints incorporated all adverse
events including severe hypoglycemia
(requiring third-party assistance) [13],
hypoglycemic events [20], sensor insertion or
sensor wear-related symptoms, diabetic
ketoacidosis or hyperosmolar hyperglycemic
state episodes, and cardiac events.
Statistical Analysis
This study was powered at 90% to detect a
difference of 3.8 mmol/mol (0.35%) in HbA1c
between the intervention and control group at
6 months with a 5% significance level as per
guidance of the Food and Drug Administration
[21] and assuming SD for the change of 0.65
[22]. The intervention group was double the size
of the control group resulting in a sample size of
210 participants allowing for a dropout rate of
20% post-randomization. Missing values for the
primary endpoint were imputed using the last
observation carried forward (LOCF) approach.
For the sensor data derived secondary
endpoints, if less than 72 h of sensor results
were available from the final 14-day sensor wear
(days 194–208), the last 72 h of available
recorded results were used. Analysis of
covariance was used to adjust for chance
imbalances in baseline measurements between
the treatment groups [23], adjusted means were
then used to compare differences between the
groups for the 6-month endpoints.
Glycemic control and variability results,
BMI/weight, and total daily dose of insulin
were compared between treatment groups using
analysis of covariance of the differences
between post-baseline and baseline values with
study center and baseline measurement as
covariates.
Changes in questionnaire responses were
considered using analysis of covariance on
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baseline values and study center to compare
scores from intervention with control group
participants.
Confidence intervals were calculated for the
group least-square mean of each measure and
the difference between group least-square
means.
Results presented here are for the full
analysis set, which included all randomized
participants since there were no pregnancies.
Data analysis was performed by a contract
research organization (ICON PLC; Dublin,
Ireland, managed by Abbott Diabetes Care)
and by Abbott Diabetes Care. We used SAS
version 9.2 or higher for all analyses.
The trial is registered with ClinicalTrials.gov
(NCT02082184).
Role of the Funding Source
The sponsor designed the study protocol in
collaboration with the principal investigator in
each country and provided all study materials.
The sponsor was involved in collecting data and
reporting results, but was not involved in the
authors’ interpretation or text writing. The
sponsor also gave approval to submit for
publication. The corresponding author had
full access to all the data in the study and,
together with all authors, had final
responsibility for the decision to submit for
publication.
RESULTS
We recruited 302 participants between March
13 and October 15, 2014; 224 were randomized
(149 intervention, 75 controls) after completing
the baseline phase (Fig. 1). Prior to
randomization 78 participants discontinued,
the primary reason for this was failure to meet
screening HbA1c criterion. Participants’
baseline characteristics are summarized in
Table 1, the full analysis set included 224
randomized participants, and there were no
significant differences between groups.
Fig. 1 Trial proﬁle
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Table 1 Baseline characteristics
Intervention (N5 149) Control (N5 75)
Age (years) 59.0 ± 9.9 (33, 81) 59.5 ± 11.0 (22, 80)
Weight (kg) 98 ± 21 (51, 170) 99 ± 19 (61, 161)
BMI (kg/m2) 33.1 ± 6.2 (18.8, 54.1) 33.3 ± 5.5 (23.7, 52.4)
Duration of diabetes (years) 17 ± 8 (2, 43) 18 ± 8 (4, 37)
Duration of insulin use (years) 9 ± 6 (0, 40) 10 ± 7 (1, 35)
Screening HbA1c (mmol/mol) 72.0 ± 10.6 (59, 103) 73.5 ± 11.3 (59, 104)
(%) 8.74 ± 0.97 (7.5, 11.6) 8.88 ± 1.04 (7.5, 11.7)
Self-reported blood glucose frequency per day 3.6 ± 1.28 (1, 10) 3.9 ± 1.33 (2, 10)
Insulin, total daily dose
Basal (units) 40.4 ± 22.6 (n = 138) 42.3 ± 25.1 (n = 70)
Bolus (units) 50.5 ± 32.5 (n = 141) 54.8 ± 32.7 (n = 70)
CSII (units) 76.9 ± 49.8 (n = 8) 82.6 ± 37.0 (n = 3)
Gender, male 94 (63%) 56 (75%)
White 141 (95%) 70 (93%)
Black 2 (1%) 1 (1%)
Asian/Paciﬁc Islander 3 (2%) 2 (3%)
Other 3 (2%) 2 (3%)
Insulin pen device 140 (94%) 71 (95%)
CSII 8 (5%) 4 (5%)
Insulin syringe 1 (1%) 0 (0%)
Previous CGM use 11 (7%) 4 (5%)
Employed 62 (42%) 34 (45%)
Not employed/retired/other 83 (56%) 40 (53%)
Insulin management training
\1 year ago 44 (30%) 28 (37%)
[1 year ago 100 (67%) 42 (56%)
Carbohydrate counting training
\1 year ago 44 (30%) 27 (36%)
[1 year ago 53 (36%) 25 (33%)
Bolus dose titration based on meal content 96 (64%) 47 (63%)
Bolus dose titration based on current glucose level 116 (78%) 60 (80%)
Bolus dose titration using sliding scale 57 (38%) 32 (43%)
Data are presented as mean ± SD (min, max) or n (%)
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There was no difference in HbA1c change at
6 months between intervention and control
groups [-3.1 ± 0.75 mmol/mol (adjusted
mean ± SE), (-0.29 ± 0.07%) and -3.4 ± 1.04,
(-0.31 ± 0.09%), respectively; p = 0.8222]. A
similar drop in HbA1c was detected in both
groups comparing study end to baseline values.
In participants younger than 65 years, a
prespecified subgroup, the drop in HbA1c was
more pronounced in the intervention group
compared with controls [-5.7 ±
0.96 mmol/mol, (adjusted mean ± SE)
(-0.53 ± 0.09%) and -2.2 ± 1.31 mmol/mol
(-0.20 ± 0.12%), respectively; p = 0.0301
(Supplementary Material p. 2)]. A significant
interaction between treatment group and age
was observed for change in HbA1c (p = 0.0017).
In participants aged 65 years or more, the
drop in HbA1c was more pronounced for the
controls compared to the intervention group
[-5.4 ± 1.45 mmol/mol (-0.49 ± 0.13%)] and
[-0.6 ± 1.09 mmol/mol (-0.05 ± 0.10%),
respectively, p = 0.0081 (Supplementary
Material p. 3)].
Significant reductions in all sensor measures
of time spent in hypoglycemia, number of
events, and area under the curve were
observed for intervention participants
compared with control (Table 2, Fig. 2, and
Supplementary Material pp. 4–7).
Time in hypoglycemia [\3.9 mmol/L
(70 mg/dL)] reduced by 43% (-0.47 ±
0.13 h/day; mean ± SE) for intervention
participants compared with control (p = 0.0006).
Time in hypoglycemia [\3.1 mmol/L
(55 mg/dL)] reduced by 53% (-0.22 ±
0.068 h/day) for intervention participants
compared with control (p = 0.0014).
Time in hypoglycemia [\2.5 mmol/L (45 mg/
dL)] reduced by 64% (-0.14 ± 0.04 h/day) for
intervention participants compared with control
(p = 0.0013).
Nocturnal hypoglycemia [\3.9 mmol/L
(70mg/dL), 23.00–06.00 h] reduced by 54%
(-0.29 ± 0.08 h per 7 h) for intervention
participants compared with control
(p = 0.0001).
Daytime hypoglycemia [\3.9 mmol/L
(\70 mg/dL), 06.00–23.00 h] reduced by 31%
(-0.16 ± 0.08 h per 17 h) for intervention
participants compared with control
(p = 0.0374).
The frequency of events with glucose
\3.9 mmol/L (70 mg/dL) reduced by 28%
(-0.16 ± 0.065 per day mean ± SE) for
intervention participants compared with
controls (p = 0.0164). Events \3.1 mmol/L
(55 mg/dL) reduced by 44% (-0.12 ± 0.037)
for intervention participants compared with
controls (p = 0.0017). Frequency of events
\2.5 mmol/L (45 mg/dL) reduced by 49%
(-0.06 ± 0.02) for intervention participants
compared with controls (p = 0.0098).
A between-group difference for area under
the curve of 51% (-7.80 ± 2.20 h/day 9 mg/dL
mean ± SE) for sensor glucose level \3.9
mmol/L (70 mg/dL) was observed for
intervention versus control participants
(p = 0.0005). For sensor glucose levels
\3.1 mmol/L (55 mg/dL), area under the curve
reduced by 60% (-2.51 ± 0.76 h/day 9 mg/dL)
for intervention participants compared with
controls (p = 0.0012). Area under the curve
was also significantly reduced by 67%
(-0.70 ± 0.22 h/day 9 mg/dL) at glucose levels
\2.5 mmol/L (45 mg/dL) for intervention
compared with control participants
(p = 0.0015).
For the prespecified subgroup aged less than
65 years, time in hypoglycemia [\3.9 mmol/L
(70 mg/dL)] reduced by 35% for intervention
participants compared to control
(-0.37 ± 0.168 h/day, p = 0.0279) with 40%
reduction in area under the curve (p = 0.0305)
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and no difference in the number of events. A
trend towards reduced time and events for
hypoglycemia at other thresholds was
observed (Supplementary Material p. 2).
For participants 65 years or more, time in
hypoglycemia (\3.9 mmol/L [70 mg/dL])
reduced by 56% for intervention participants
compared to control (-0.60 ± 0.220,
p = 0.0083) with 71% reduction in area under
the curve (p = 0.0061). No difference was
detected in number of events (p = 0.0513).
Reduced time, events, and area under the
curve for hypoglycemia at other thresholds
was observed (Supplementary Material p. 3).
There was no difference in time in range
(3.9–10.0 mmol/L (70–180 mg/dL)] between
intervention and control participants
[p = 0.7925, (Table 2)].
There was no difference in time in
hyperglycemia [ 10.0 mmol/L (180 mg/dL) and
[13.3 mmol/L (240 mg/dL)] between the two
groups (Table 2).
A number of glucose variability measures
were explored and an improvement for
intervention participants was observed (Table 2
and Supplementary Material pp. 8–9).
Glucose variability measured as coefficient of
variation (CV) reduced by 2.26 ± 0.71%
mean ± SE for intervention participants
compared with controls (p = 0.0017). LBGI
reduced by 0.3 ± 0.11 mean ± SE for
intervention participants compared with
controls (p = 0.0029). CONGA was reduced for
intervention compared with controls by 3 ± 1.3
mg/dL mean ± SE at 2 h time interval
(p = 0.0385), by 5 ± 2.2 at 4 h (p = 0.0133),
and by 8 ± 3.0 at 6 h (p = 0.0046).
Self-monitoring blood glucose frequency for
intervention participants fell from
3.8 ± 1.4 tests/day mean ± SD (3.8 tests/day
median) at baseline to 0.5 ± 1.1 (0.1 median)
from the first unblinded sensor wear with full
access to sensor glucose data (day 15–31),
reducing further to 0.4 ± 1.0 tests/day (0.0
median) by study end (day 208). The overall
blood glucose monitoring rate over 6 months
was 0.3 ± 0.7, median 0.1 (Fig. 3).
During the treatment phase (day 15
onwards) average sensor-scanning frequency
was 8.3 ± 4.4 (mean ± SD) times/day (median
6.8), i.e., double the frequency of blood glucose
testing (Fig. 3). There was no significant
difference in the number of scans performed
by those \65 years and C65 years of age
[8.1 ± 4.6 (median 6.8) and 8.5 ± 4.1 (median
6.9), respectively, p = 0.6627].
There was no correlation between frequency
of sensor scanning and reduced time in
hypoglycemia or change to HbA1c. Device use
for the intervention group (n = 138) was
88.7 ± 9.2% (defined as the percentage of data
Fig. 2 Difference in intervention and control groups for
time in range and hypoglycemia measures. Rescaled
conﬁdence intervals are conﬁdence intervals for the
difference in the intervention and control group at
6 months expressed as a percentage of the control group
adjusted mean
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collected, assuming continuous device wear for
6 months).
Self-monitoring of blood glucose frequency
for control participants was 3.9 ± 1.5 test/day
(median 3.9) at baseline and this rate was
maintained until study end [3.8 ± 1.9 (median
3.9), Fig. 3]. Control group participants
\65 years performed less blood glucose
monitoring tests (2.78 ± 1.08 test/day) than
those C65 years (3.46 ± 0.94), p = 0.0247.
At baseline, 95% of participants used an
insulin pen device or syringe for intensive
insulin therapy, with the remainder (5%) on
CSII (Table 1); 78% used analogue insulin, seven
participants from each group (n = 14) utilized
human insulin, and 35 participants used both
human and analogue insulin (intervention
n = 22, control n = 13).
There was no difference detected in total
daily dose of insulin, basal, or bolus insulin
doses between the two groups. None of the
changes in insulin were correlated with the
treatment effect on HbA1c or time in
hypoglycemia (\3.9 mmol/L [70 mg/dL]).
There was no difference in total daily dose of
insulin by study end for intervention
participants (from 87.6 ± 44.0 (mean ± SD) to
85.2 ± 39.7 units) compared with controls
(from 90.1 ± 40.6 to 87.8 ± 41.5),
-0.4 ± 3.75 units mean ± SE (p = 0.9059).
Basal insulin was similar for intervention and
control participants (-2.3 ± 1.96 units
mean ± SE, p = 0.2498). Bolus insulin was
similar for intervention and control
participants (1.4 ± 2.53 units mean ± SE,
p = 0.5856). Similarly, for participants above or
below 65 years, there was no difference detected
in the total daily dose of insulin (0.7 ± 4.86,
p = 0.8871; and -3.3 ± 5.40, p = 0.5403,
respectively).
There were no changes in body weight
(p = 0.2496) or BMI (p = 0.2668) from baseline
for either group.
Total treatment satisfaction score for DTSQ
(status versus change) was significantly
improved for intervention group participants
(13.1 ± 0.50, mean ± SE) compared with
controls (9.0 ± 0.72), p\0.0001. Satisfaction
with treatment results using DQoL
demonstrated significant improvement for the
intervention group (-0.2 ± 0.04, mean ± SE)
versus the control group (0.0 ± 0.06),
p = 0.0259, for this element of the
questionnaire. There were no other significant
differences observed in other aspects of DTSQ
Fig. 3 Glucose monitoring frequency (a) and total num-
ber of scans by time of day in the intervention group (b).
Number of scans performed across all intervention
participants over 6 months by time of day. BGM blood
glucose monitoring
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Fig. 4 Scores from DTSQ (a) and DQoL
(b) questionnaires. Error bars show 95% CIs. DTSQ
treatment satisfaction scores range from -18 to 18; high
scores indicate much more satisﬁed, convenient, ﬂexible, or
likely to recommend treatment now. DTSQ perceived
frequency scores range from -3 to 3; high scores indicate
much more time now. DQoL scores range from 1 to 5;
high scores indicate dissatisfaction, frequent impact, or
frequent worry. DQoL Diabetes Quality of Life Question-
naire, DTSQ Diabetes Treatment Satisfaction
Questionnaire
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and DQoL or for the DDS scales (Fig. 4,
Supplementary Material p. 10).
User questionnaire results showed
intervention participants agreed with positive
aspects of the device including use, comfort,
and utilization of sensor glucose information
(Supplementary Material p. 11).
The system was used for 6 months by
intervention participants and worn (blinded)
for 4 weeks by control participants (n = 224). In
total, serious adverse or adverse events (n = 515)
were experienced by 114 (76.5%) intervention
and 47 (62.7%) control participants.
There were no serious adverse events related
to the device or study procedure. Forty-two
serious events were experienced by 16 (10.7%)
intervention and 12 (16.0%) control
participants.
Four hypoglycemia serious adverse events
were experienced by four participants (three
intervention and one control) and 57
hypoglycemia adverse events by 10 (7%)
intervention and seven (9%) control
participants.
None of the severe hypoglycemic episodes
[13] or hypoglycemic adverse events were
associated with the device.
Three participants (one intervention, two
controls) experienced an adverse event leading
to withdrawal from the study; none were
associated with the device.
Six (4.0%) intervention participants reported
nine device-related adverse events (two severe,
six moderate, and one mild). These were
sensor-adhesive reactions, primarily treated
with topical preparations. All were resolved at
study exit.
There were no reported events of diabetic
ketoacidosis or hyperosmolar hyperglycemic
state. Seven cardiac events were reported for
four (2.7%) intervention and three (4.0%)
control participants (none were considered to
be related to study procedures or the device).
Anticipated symptoms refer to those
typically expected using a sensor device and
equate to symptoms normally experienced with
blood glucose finger-stick testing, e.g., pain,
bleeding, bruising. There were 158 anticipated
sensor insertion site symptoms observed for 41
(27.5%) intervention and 9 (12.0%) control
participants. These symptoms were primarily
(63%) due to the sensor adhesive (erythema,
itching, and rash) and resolved without medical
intervention. Adverse events and anticipated
symptoms associated with the insertion of the
sensor and sensor wear are summarized in
Table 3 and Supplementary Material p. 12.
DISCUSSION
This European study is the first to investigate
the use of flash sensor-based glucose technology
as a replacement for standard self-monitoring of
blood glucose in individuals with type 2
diabetes treated with intensive insulin therapy.
Whilst the primary endpoint was not achieved
(no difference in HbA1c change between the
groups at 6 months), the secondary endpoints
demonstrate a number of interesting findings
for further consideration including use of the
technology is associated with reduced time in
hypoglycemia, particularly nocturnal;
treatment satisfaction improved across two
questionnaire methodologies; HbA1c
improvement combined with reduced
hypoglycemia measures were observed in the
\65 years subgroup; and the safety data
confirms that flash glucose monitoring
technology is an effective and safe
replacement for blood glucose monitoring.
There is a paucity of data on continuous
glucose monitoring (CGM) use in type 2
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diabetes and, to our knowledge, no recent
randomised, controlled studies in this
population using intensive insulin therapy.
Available data for CGM use in those using oral
glucose-lowering medication or basal insulin
with higher baseline HbA1c values indicate they
are more likely to show benefit with a reduction
in this clinical marker [24–26]. However,
hypoglycaemia was not an endpoint in these
studies, and exposure to hypoglycaemic risk is
much less in treatment regimens excluding
prandial insulin. Reductions in hypoglycaemic
markers generally require de-escalation of
glucose-lowering therapy [27] with less
stringent glucose targets [28]. In the
intervention group, HbA1c level improved
with significantly reduced exposure to
hypoglycaemia.
Reductions in hypoglycemia in the
intervention group were present across all age
groups, particularly significant in those aged
above 65 years, and over 24 h of the day, with
benefit particularly pronounced during
nighttime. Reduced nocturnal hypoglycemia
likely resulted through learning from historical
nighttime sensor glucose data leading to
adjustments in pre-bedtime snacks or
overnight basal insulin doses. Improved
daytime hypoglycemia was likely achieved
through a combination of on-demand access
to real-time sensor glucose results with trend
arrows, enabling preventative action and
informing behavior modification, alongside
HCP review of glucose reports with the
participant, to alter the balance of insulins.
Smaller, daily adjustments to insulin doses or
proportions may not be apparent in the total
insulin dose [29]. Given the association of
hypoglycemia with adverse clinical outcome,
including enhanced risk of cardiovascular
events, increased hospital admissions, and
reduced survival [5, 7], these results for
multiple hypoglycemia-related secondary
endpoints highlight the effectiveness and
safety of this technology and its potential for
improving glycemic control. Detection of
Table 3 Adverse events
Intervention (N5 149) Control (N5 75)
Participants (%) with adverse or serious adverse events 114 (77%) 47 (63%)
Number of adverse events (excluding serious events) 316 157
Participants (%) with serious adverse events 16 (11%) 12 (16%)
Number of serious adverse events 20 22
Participants with hypoglycemic serious adverse events 3 (2%) 1 (1%)
Number of hypoglycemic serious adverse events 3 1
Participants (%) with hypoglycemic adverse events 10 (7%) 7 (9%)
Number of hypoglycemic adverse events 27 30
Participants (%) with device-related adverse events 6 (4%) 0
Number of device-related adverse events 9* 0
Number of adverse events leading to discontinuation 1 3
Participants (%) discontinuing due to adverse events 1 (1%) 2 (3%)
* All sensor adhesive reactions; 2 severe, 6 moderate, and 1 mild
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hypoglycemia, especially nocturnal, can be
difficult with intermittent glucose monitoring
even when it is performed frequently.
Once intervention participants were able to
see sensor glucose readings, their blood glucose
testing frequency fell to around 1 test every
3 days, with 57% of participants testing less
than once every 10 days. High device utility rate
(89%) [22] with average sensor scanning eight
times daily replaced blood glucose testing and
shows confident use of the technology to access
current and historic sensor glucose data. In
contrast, although the control group remained
concordant with regular blood glucose testing
throughout the study (averaging 3–4 tests
daily), they did not benefit from a reduction
in hypoglycemia.
In addition to benefiting from less time in
hypoglycemia compared with the control group,
intervention participants showed improvement
in glucose variability [30] and LBGI, a specific risk
marker for hypoglycemia [31]. These findings
can be partially explained by the documented
association between hypoglycemia and glucose
variability [30, 31]. The reduction in
hypoglycemic exposure in the intervention
group may offer additional clinical benefits [8, 9].
A significant improvement in HbA1c was
detected in those younger than 65 years.
Although the reasons for this finding are not
entirely clear we hypothesize that the
convenience associated with sensor glucose
readings, compared with blood glucose testing,
prompted more frequent testing. This supports
a recent study reporting younger participants as
being ‘‘too busy’’ for finger-stick testing [32].
HbA1c level was unchanged for intervention
participants C65 years. Again the reasons for
this are not entirely clear, and we hypothesize
that the benefit for older intervention
participants of being able to visualize actual or
potential hypoglycemic risk prompted a more
cautious approach to therapy adjustments for
this vulnerable group, prioritizing
hypoglycemia reduction over a more
indiscriminate approach to glucose control.
The overall impact of these two approaches to
care was no effect on HbA1c.
These findings may have future clinical
implications as past studies show worse
glycemic control in younger participants with
type 2 diabetes [3, 4] and this new sensor-based
technology may be helpful for these participants.
However, no adjustments were made for
multiple testing by subgroup and future work is
required to confirm this observation.
Participants in the intervention group had
improvedquality of life and satisfactionwith their
treatment compared with control. The visual
presentation of the historical glucose profile and
ease of testing with flash glucose monitoring,
avoidance of blood glucose testing, and reduced
concerns about hypoglycemia probably
contributed to improved quality of life and
satisfaction with treatment. A recent study
investigating insulin-treated participants on
continuous glucose monitoring has shown,
similar to our study, improved quality of life
measures, attributed to various factors including
reduced fear of hypoglycemia, greater confidence,
and perceived control over diabetes [33].
Our study results support those of a recent
randomized control trial comparing use of this
technology with blood glucose testing in adults
with well-controlled type 1 diabetes, which also
demonstrated superior reduction in
hypoglycemia without deterioration of HbA1c
and improved treatment satisfaction [34].
Limitations of this work include the absence of
a treatment algorithm for modifying insulin
therapy. Our aim was to test the new
technology in ‘‘real-world settings’’ according to
local practices in different centers. Having
restrictive protocols for treatment changes
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would have made general applicability of our
data uncertain. Our inclusion of only adults with
intensive insulin therapy performing regular
glucose testing means future studies to assess
the effectiveness of this novel glucose-sensing
technology in younger, less concordant,
individuals with type 2 diabetes are needed.
Had there been an insulin treatment algorithm
and inclusion of participants with less regular
blood glucose testing, the similar decline in
HbA1c observed in both groups during the
short period of this study may have been
different. Common to glucose technology
studies, our intervention was non-masked to
subjects as sensor wear was experienced by all
with assessment and some treatment decisions
based on the same sensor glucose values [35]. No
adjustment was made for multiple testing of
secondary endpoints. Many of the endpoints,
particularly those derived from sensor glucose
values, are highly inter-related and should not be
considered in isolation.
CONCLUSION
In summary, use of sensor glucose readings
resulted in similar drop in HbA1c compared
with standard methods of blood glucose testing.
When compared with self-monitored blood
glucose testing there were no safety concerns
and use of this new technology was associated
with highly significant reductions in
hypoglycemic measures across all age groups,
decreased glucose variability, and improved
quality of life and treatment measures.
Collectively these results demonstrate that
flash glucose-sensing technology is safe and
effective when used in place of standard
self-monitoring of blood glucose for glycemic
management of type 2 diabetes treated by
intensive insulin therapy.
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